Monitor for upcoming Phase 3 trial initiation for PSX-001, as the new regulatory environment may accelerate development timelines. The strong Phase 2 data and regulatory tailwinds could attract partnership interest.
Price Chart
Executive Summary
Incannex Healthcare announced that its PSX-001 oral synthetic psilocybin program aligns with a new White House Executive Order aimed at accelerating access to psychedelic treatments for serious mental illness. The company highlighted strong Phase 2 clinical trial data for PSX-001 in treating Generalized Anxiety Disorder (GAD), including a 12.8-point reduction in anxiety scores versus placebo, and noted it has over $70 million in cash with no debt.
Key Facts
- Incannex Healthcare supports a new White House Executive Order titled 'Accelerating Medical Treatments for Serious Mental Illness'.
- The company's PSX-001 program, an oral synthetic psilocybin therapeutic for Generalized Anxiety Disorder (GAD), aligns with the goals of the Executive Order.
- In a completed Phase 2 clinical trial, PSX-001 demonstrated a 12.8-point reduction in HAM-A anxiety scores versus 3.6 points for placebo (p<0.0001).
- The trial also showed a 44% clinically meaningful response rate (four times the placebo rate) and a 27% remission rate (five times the placebo rate), sustained through 11 weeks.
- There were no serious adverse events and only a single discontinuation across 73 patients.
- The Executive Order directs the FDA to prioritize review of psychedelic compounds with Breakthrough Therapy designations and initiate DEA rescheduling upon successful Phase 3 completion.
- Incannex reports it is well-funded with over $70 million in cash and no debt, and its U.S. IND for PSX-001 is active.
Financial Impact
The company reported having over $70 million in cash and no debt, providing strong financial runway for the PSX-001 program.
Risk Factors
- The drug candidate PSX-001 is still in development and must successfully complete Phase 3 trials to gain approval.
- The company's future depends heavily on the success of a single drug candidate, PSX-001, creating significant concentration risk.
- Regulatory changes, while favorable, are still in early stages and may not lead to the anticipated faster approval timelines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-046408 |
| Document: ea028729701ex99-1.htm | 0001213900-26-046408 |
| Document: 0001213900-26-046408-index-headers.html | 0001213900-26-046408 |
| Document: 0001213900-26-046408-index.html | 0001213900-26-046408 |
| Document: 0001213900-26-046408.txt | 0001213900-26-046408 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $3.23 $3.18 | ▼ −1.55% | ▼ −3.49% | $2.68 (−17.03%) |
Aug 25, 2026 9w ago | 8-K | $3.75 $3.45 | ▼ −8.13% | ▼ −9.11% | $2.68 (−28.53%) |
Aug 11, 2026 11w ago | 8-K | $3.20 $3.23 | ▲ +0.94% | ▲ +2.00% | $2.68 (−16.25%) |
Jul 23, 2026 13w ago | Press Release | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.68 (−15.19%) |
Jul 23, 2026 13w ago | 8-K | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.68 (−15.19%) |
Jun 10, 2026 19w ago | Press Release | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.68 (−31.46%) |
Jun 10, 2026 19w ago | 8-K | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.68 (−31.46%) |
Jun 9, 2026 20w ago | 8-K | $3.67 $3.71 | ▲ +1.09% | ▼ −0.36% | $2.68 (−26.98%) |
May 14, 2026 23w ago | Press Release | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.68 (−30.93%) |
May 14, 2026 23w ago | 8-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.68 (−30.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers